AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38365952
Drug: Higher-dose osocimab
RxNorm normalized name: Osocimab
DrugBank: Osocimab (DB14818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose osocimab
Trial: 38366021
Drug: MTB advised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTB advised molecular-guided treatment options
Trial: 38366225
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of small and ultrasmall graphene oxide nanosheets at a concentration of 200 μg/m3
Trial: 38366267
Drug: Ambrisentan (2.5/5/7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (2.5/5/7.5 or 10 mg/day)
Trial: 38366324
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 20 μg
Trial: 38366324
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (fentanyl 100 μg and lidocaine 80 mg)
Trial: 38366591
Drug: BNT166a (quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT166a (quadrivalent vaccine)
Trial: 38366591
Drug: BNT166c (trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT166c (trivalent vaccine)
Trial: 38366591
Drug: BNT166a and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT166a and BNT166c (both vaccines)
Trial: 38366621
Drug: Tofacitinib (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (in treatment-naïve subpopulation)
Trial: 38366621
Drug: TNFi (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi (in treatment-naïve subpopulation)
Trial: 38366886
Drug: Apatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib plus toripalimab (250 mg apatinib per day plus 240 mg toripalimab on day 1 per 3 weeks)
Trial: 38366886
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of chemotherapy (PC)
Trial: 38366909
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (2 × 10^6 cells)
Trial: 38366909
Drug: Medium-dose group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose group (20 × 10^6 cells)
Trial: 38366909
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (80 × 10^6 cells)
Trial: 38367207
Drug: 12-week timing
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week timing and coordination physical therapy intervention
Trial: 38367405
Drug: On-treatment modified
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment modified Glasgow prognostic score (mGPS) assessed at week six in atezolizumab-treated subgroup
Trial: 38367405
Drug: On-treatment modified
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment modified Glasgow prognostic score (mGPS)
Trial: 38367750
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg vaginal misoprostol (subgroup: multiparous patients)
Trial: 38367750
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg vaginal misoprostol (subgroup: multiparous patients)
Trial: 38367750
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (25 μg and 50 μg)
Trial: 38367966
Drug: Nudge intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nudge intervention consisting of three text message reminders with four behavioural nudges: (1) social norm messages, (2) different messengers through links to short educational videos, (3) a pledge to have their child vaccinated, (4) information salience through links to guidelines and vaccine safety information.
Trial: 38368603
Drug: Somapacitan (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan (0.16 mg/kg/week) after continuous treatment
Trial: 38368603
Drug: Somapacitan (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan (0.16 mg/kg/week) after switch from daily GH
Trial: 38368901
Drug: Targeted anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted anticoagulation according to TRiP(cast) score (no prescription if score <7, anticoagulation if score ≥7)
Trial: 38368901
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase (anticoagulation prescription according to physician's usual practice)
Trial: 38369233
Drug: Parenteral thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral thiamine (100 mg daily) for ≥3 days
Trial: 38369528
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate solution (RAS)
Trial: 38369573
Drug: PRV-101 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRV-101 (low dose)
Trial: 38369573
Drug: PRV-101 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRV-101 (high dose)
Trial: 38369573
Drug: PRV-101 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRV-101 (low dose and high dose)
Trial: 38369805
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment (not specified, but includes proteasome inhibitor-based combination therapy)
Trial: 38369805
Drug: Proteasome inhibitor
RxNorm normalized name: Proteasome inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proteasome inhibitor (PI)-based combination therapy
Trial: 38369805
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy in patients with extramedullary disease at baseline
Trial: 38371290
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg inclisiran sodium on days 1, 90, and 270
Trial: 38371314
Drug: octocog alfa
RxNorm normalized name: Octocog alfa
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: octocog alfa (on-demand therapy)
Trial: 38371479
Drug: Dulaglutide 1.5
RxNorm normalized name: dulaglutide 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 1.5 mg subcutaneously once weekly for 12 weeks
Trial: 38371479
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously once weekly for 12 weeks
Trial: 38372621
Drug: Double-dose dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose dolutegravir (50 mg twice daily)
Trial: 38372621
Drug: Standard-dose dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dolutegravir
Trial: 38372621
Drug: Double-dose dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose dolutegravir
Trial: 38372622
Drug: Propafenone (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (70 mg bolus followed by 400-840 mg/24 h)
Trial: 38372622
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg bolus followed by 600-1800 mg/24 h)
Trial: 38372727
Drug: Cadonilimab 15
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 15 mg/kg every 3 weeks plus chemotherapy
Trial: 38372727
Drug: Cadonilimab 10
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy
Trial: 38372727
Drug: Cadonilimab 10
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab
Trial: 38372727
Drug: Cadonilimab 10
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab (combined with cohort A-10)
Trial: 38372727
Drug: Cadonilimab combined
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab combined with standard therapy
Trial: 38372904
Drug: Everolimus (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (oral daily for 52 weeks)
Trial: 38372938
Drug: GSK2982772 (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 (960 mg once-daily modified-release formulation)
Trial: 38372949
Drug: PY314 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PY314 10 mg/kg in combination with pembrolizumab 200 mg IV every 21 days
Trial: 38372981
Drug: Sublingual edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg)
Trial: 38372981
Drug: Placebo (edaravone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (edaravone, 0 mg; dexborneol, 60 μg)
Trial: 38373857
Drug: Early Detection
RxNorm normalized name: Leader Early Detection Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Detection and Treatment to Reduce Events with Agitation Tool (ED-TREAT)
Trial: 38374026
Drug: Post-transplantation cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation cyclophosphamide (PTCy) 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis
Trial: 38374026
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis
Trial: 38374062
Drug: Metronomic trabectedin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic trabectedin combined with low-dose cyclophosphamide
Trial: 38374347
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule)
Trial: 38375038
Drug: Remimazolam combined
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam combined with low dose esketamine
Trial: 38375038
Drug: Propofol combined
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol combined with low dose esketamine
Trial: 38375429
Drug: Inhaled APN01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled APN01 (rhACE2)
Trial: 38375580
Drug: Treatment-as-usual (n=12)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (n=12)
Trial: 38375995
Drug: Lacosamide (8-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (8-12 mg/kg/day)
Trial: 38376229
Drug: Posaconazole intravenous
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole intravenous (IV) and powder for oral suspension (PFS) formulations at dosing regimens of 3.5, 4.5, and 6 mg/kg
Trial: 38376229
Drug: Posaconazole 300
RxNorm normalized name: posaconazole 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 300 mg/day tablet in a virtual adolescent population (body weight >40 kg)
Trial: 38376591
Drug: Seawater nasal
RxNorm normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seawater nasal wash (4-daily nasal washes with undiluted isotonic seawater)
Trial: 38376596
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (HyA)
Trial: 38376645
Drug: Zonisamide 25
RxNorm normalized name: zonisamide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 25 mg
Trial: 38376645
Drug: Zonisamide 50
RxNorm normalized name: zonisamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 50 mg
Trial: 38376643
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) + topical timolol-dorzolamide eye drops
Trial: 39446746
Drug: Facilitated directly
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated directly observed therapy (DOT)
Trial: 39446746
Drug: Facilitated self-administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facilitated self-administered therapy (SAT)
Trial: 38377520
Drug: Fluoxetine; dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine; dosage and duration not available
Trial: 38377526
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without pharmacogenetic testing)
Trial: 38377775
Drug: Matched targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched targeted therapy
Trial: 38377775
Drug: Non-matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-matched treatment
Trial: 38377775
Drug: Matched targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched targeted therapy outside a clinical trial
Trial: 38377773
Drug: TLD-1 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLD-1 administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) starting dose of 10 mg/m², maximum administered dose of 45 mg/m², RP2D defined at 40 mg/m².
Trial: 38377869
Drug: Simvastatin add-on
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin add-on treatment
Trial: 38378522
Drug: Collagen patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen patch cover (CPC)
Trial: 38378568
Drug: Kefir administration
RxNorm normalized name: Lentilactobacillus kefiri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir administration (60 mL, followed by 120 mL after 12 h, then 240 mL daily)
Trial: 38378568
Drug: Kefir administration
RxNorm normalized name: Lentilactobacillus kefiri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir administration
Trial: 38378678
Drug: Denosumab (RANKL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (RANKL inhibitor)
Trial: 38378735
Drug: Evidence-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based therapies (EBTs) including antithrombotic drugs
Trial: 38378937
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam besylate loading dose
Trial: 38380420
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10 mg (TEL/ALD/RSV)
Trial: 38380420
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Atorvastatin 10 mg (ALD/ATV)
Trial: 38380699
Drug: L-serine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-serine treatment for 52 weeks
Trial: 38380779
Drug: Thin buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin buccal bone group
Trial: 38380779
Drug: Thick buccal
RxNorm normalized name: tick-borne encephalitis purified antigen Prefilled Syringe [Ticovac]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick buccal bone group
Trial: 38380807
Drug: Acyclic retinoid
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclic retinoid (ACR) treatment for 4 weeks
Trial: 38380940
Drug: Standard initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initiation of Renal Replacement Therapy (RRT)
Trial: 38380940
Drug: Accelerated initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Accelerated initiation of Renal Replacement Therapy (RRT)
Trial: 38381068
Drug: Recreational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational drug users (41 patients, 12.6% positive multidrug test)
Trial: 38381068
Drug: Recreational drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational drug users
Trial: 38381068
Drug: Non-recreational drug
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-recreational drug users (control group)
Trial: 38381283
Drug: Pulmonary hypertension
RxNorm normalized name: Alyq 20 MG Pulmonary Hypertension Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary hypertension (PH)-targeted therapy
Trial: 39661372
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg per day)
Trial: 38381417
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Trial: 38381417
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture (minimal needling, 1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Trial: 38381476
Drug: Internet-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Based Cognitive Behavioral Therapy (ICBT)
Trial: 38381664
Drug: Seladelpar (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seladelpar (10 mg daily)
Trial: 38381752
Drug: Community delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community delivery of antiretroviral therapy (ART)
Trial: 38381905
Drug: Micronized/ultramicronized palmitoylethanolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized/ultramicronized palmitoylethanolamide (m/umPEA) 600 mg twice daily for 3 months
Trial: 38381905
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (did not accept m/umPEA therapy)
Trial: 38381930
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug in combination with paracetamol for 3 weeks
Trial: 38383005
Drug: Preemptive IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive IV acetaminophen 15 mg/kg after anesthetic induction/before surgical incision
Trial: 38383005
Drug: Preventive IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive IV acetaminophen 15 mg/kg at the end of surgery/before skin closure
Trial: 38383268
Drug: Low-pressure hyperbaric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-pressure hyperbaric oxygen therapy (HBOT), 8-week intervention (5 sessions per week)
Trial: 38790008
Drug: Opioid maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid maintenance treatment (OMT)
Trial: 38383367
Drug: Ivermectin (IVM)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin (IVM) - 3 months of treatment
Trial: 38383367
Drug: Dihydroartemisinin-piperaquine (DHP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHP) - 3 months of treatment
Trial: 38383426
Drug: Digital psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital psychological self-care (DPSC) with mid-treatment interview guidance
Trial: 38383426
Drug: Digital psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital psychological self-care (DPSC) with weekly written messages guidance
Trial: 38383462
Drug: Liraglutide (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (daily injections for at least 13 weeks before and 52 weeks after AF ablation)
Trial: 38383476
Drug: Low-sodium bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium bread (280 mg Na/100 g) in Group C
Trial: 38383476
Drug: Standard bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bread (750 mg Na/100 g) in Group A
Trial: 38383578
Drug: AKS-452 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 (90 µg subcutaneous booster dose)
Trial: 38384123
Drug: Radial shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shockwave therapy (RSWT) - five treatments (one week apart over five-week period) to the three most painful areas (500 shocks at 1.5 bar and 15 Hz, then 1000 shocks at 2 bar and 8 Hz, and finally 500 shocks at 1.5 bar and 15 Hz)
Trial: 38384390
Drug: Exposure-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based therapy (EXP)
Trial: 38384458
Drug: Intracranial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracranial infusion of TMZ-resistant γδ T cells (genetically engineered with p140K/MGMT lentivector)
Trial: 38384458
Drug: Drug Resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Resistance Immunotherapy (DRI) combining TMZ and TMZ-resistant γδ T cells